Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme

Semaglutide is a GLP1-RA for the treatment of type 2 diabetes. Treatment with semaglutide led to significant reductions in HbA1c and body weight vs. all comparators across the SUSTAIN phase 3a clinical trial programme. In SUSTAIN 6, subjects with T2D and established cardiovascular disease or high CV risk were randomised to subcutaneous semaglutide or placebo, added to standard of care; the median duration of follow-up was 2.1 years. Semaglutide-treated patients had a significant 26% lower risk of major adverse CV events vs. those receiving placebo over 2 years.